AMPH
$19.51
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal ...
Recent News
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Generic Pharmaceuticals Stocks Q4 Highlights: Amphastar Pharmaceuticals (NASDAQ:AMPH)
Looking back on generic pharmaceuticals stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.’s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. The seventh stock among the small-cap stocks is Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). TheFly reported on February 27 that Wells Fargo reduced its price target on AMPH to $30 from $34 and kept an Overweight rating on the shares. […]